Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.

ABSTRACT:

Background

Sodium-glucose co-transporter-2 inhibitors (SGLT2is) show promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD). However, the relative efficacy of different SGLT2is remains unclear. We aimed to compare the clinical effectiveness of empagliflozin versus dapagliflozin in adults with MASLD.

Methods

Using the TriNetX database, we conducted a retrospective cohort study of adults with MASLD who were newly prescribed either empagliflozin or dapagliflozin between January 2013 and September 2024. After propensity score matching, we compared 13,274 patients in each group. The primary outcome was a composite of all-cause hospitalization, all-cause mortality, major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs), and d

SUBMITTER: Wu JY 

PROVIDER: S-EPMC12554547 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature